利肺胶囊联合四联抗结核方案治疗结核性胸膜炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R969.4;R521

基金项目:

河南省医学科技攻关计划项目(LHGQ20190342)


Clinical Study on Lifei Capsules Combined with Quadruple Anti-Tuberculosis Regimen for Tuberculous Pleurisy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察利肺胶囊联合四联抗结核方案治疗结核性胸膜炎(TBP) 的临床疗效及对胸膜厚度、 血清趋化因子的影响。方法:采用随机数字表法将98 例TBP 患者分为观察组与对照组各49 例。对照组给予 常规四联抗结核方案治疗,观察组给予利肺胶囊联合常规四联抗结核方案治疗,2 组均连续治疗2 个月。比较 2 组胸痛消失时间、胸水消失时间;比较2 组治疗前后中医证候积分、胸膜厚度、白细胞介素-10(IL-10)、 转化生长因子-β (TGF-β)、单核细胞趋化蛋白-1 (MCP-1)、调节性T 细胞(Treg)、辅助性T 细 胞(Th17)、白细胞介素-17(IL-17) 水平及Th17/Treg,并评估2 组临床疗效及不良反应发生情况。结果:治 疗2 个月后,观察组总有效率95.92%,高于对照组81.63%(P<0.05);胸痛消失时间和胸水消失时间均短 于对照组(P<0.05)。2 组中医证候积分、胸膜厚度及血清IL-10、IL-17、MCP-1、Th17、TGF-β 水平及 Th17/Treg 均较治疗前降低(P<0.05);Treg 水平升高(P<0.05),且观察组治疗后中医证候积分、胸膜厚度 及血清IL-10、IL-17、MCP-1、Th17、TGF-β 水平及Th17/Treg 均低于对照组(P<0.05),Treg 水平高于对照 组(P<0.05)。2 组均未出现不良反应。结论:利肺胶囊联合四联抗结核方案治疗TBP 疗效确切,能够降低患 者胸膜厚度,改善免疫功能和调节趋化因子水平,安全性较高。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Lifei Capsules combined with quadruple antituberculosis regimen for tuberculous pleurisy (TBP), and its effect on pleural thickness and chemotactic factors in serum. Methods: A total of 98 TBP patients were divided into the observation group and the control group according to the random number table method, with 49 cases in each group. The control group was treated with conventional quadruple anti-tuberculosis regimen,and the observation group was treated with Lifei Capsules combined with conventional quadruple anti- tuberculosis regimen. Both groups were treated continuously for two months. The disappearance time of chest pain and pleural effusion was compared between the two groups. The traditional Chinese medicine (TCM) syndrome scores, pleural thickness, and interleukin- 10 (IL- 10), transforming growth factor β (TGF- β), monocyte chemotactic protein 1 (MCP-1),regulatory T cells (Treg),helper T cells (Th17),interleukin-17 (IL-17),and Th17/Treg were compared between the two groups before and after treatment. The clinical effects and incidence of adverse reactions were evaluated in the two groups. Results: After two months of treatment, the total effective rate was 95.92% in the observation group,higher than that of 81.63% in the control group (P< 0.05). The disappearance time of chest pain and pleural effusion in the observation group was shorter than that in the control group (P<0.05). The TCM syndrome scores, pleural thickness, and serum levels of IL- 10, IL- 17, TGF- β, MCP- 1, Th17, and Th17/Treg, in the two groups were decreased when compared with those before treatment (P<0.05); and Treg levels were increased (P<0.05). After treatment,TCM syndrome scores,pleural thickness,and serum levels of IL-10,IL-17,TGF-β,MCP-1, Th17 and Th17/Treg, in the observation group were lower than those in the control group (P<0.05),and the Treg level was higher than that in the control group (P<0.05). No adverse reaction was observed in both groups. Conclusion: The combination of Lifei Capsules and quadruple anti- tuberculosis regimen has a definite curative effect on TBP, which can reduce pleural thickness, improve immune function, and regulate levels of chemotactic factors,with high safety.

    参考文献
    相似文献
    引证文献
引用本文

伏志杰,张德振,刘凤丽.利肺胶囊联合四联抗结核方案治疗结核性胸膜炎临床研究[J].新中医,2023,55(21):50-54

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-11-14
  • 出版日期:
文章二维码